ReviewMicroorganisms2021
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 71 citations in OpenAlex.
- Building a case for accelerated clinical development of drugs and vaccines - what are the driving forces?Globalization and health · 2026Article
- Antileishmanial Activity ofMolecules (Basel, Switzerland) · 2026Article
- Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Sterol Endoperoxides and Their Antileishmanial Effects: Influence on Viability, Oxygen Metabolism and Sterol Synthesis.Molecules (Basel, Switzerland) · 2026Article
- A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit.The Journal of antimicrobial chemotherapy · 2026Review
- A Human Monoclonal Antibody Targeting α-Gal Ameliorates Experimental Cutaneous Leishmaniasis.The Journal of infectious diseases · 2026Article
- Hit-Identification to Novel Antileishmanial Agents from a β‑Pinene Scaffold: from Synthesis toACS omega · 2026Article
- Exploring Lamiaceae diterpenoids as potential multitarget therapeutics for leishmaniasis and chagas disease.Molecular diversity · 2026Article
- Trypanosomatid parasites, translational research in a One Health, One World environment.Frontiers in chemistry · 2026Review
- Pathogenic Significance of Trypanosomatids: Progress in Drug Resistance, Control Strategies, and Artificial Intelligence.Interdisciplinary perspectives on infectious diseases · 2026Review
- Oral 18-methoxycoronaridine activity in simian and murineFrontiers in pharmacology · 2026Article
- Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints.BMC medical informatics and decision making · 2025Article
- Molecular docking and simulation analysis of selected herbal compounds against GP63, FPPS, and NMT, three importantResearch in pharmaceutical sciences · 2025Article
- Identification of potent inhibitors of Leishmania donovani and Leishmania infantum chagasi, the causative agents of Old and New World visceral leishmaniasis.Communications biology · 2025Article
- Plant-derived products as anti-leishmanials which target mitochondria: a review.Expert reviews in molecular medicine · 2025Review
- Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice.Acta parasitologica · 2025Article
- Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The repertoire of iron superoxide dismutases fromJournal of enzyme inhibition and medicinal chemistry · 2024Article
- NKG2C+CD57+ natural killer cells with senescent features are induced during cutaneous leishmaniasis and accumulate in patients with lesional healing impairment.Clinical and experimental immunology · 2024Article
- Identification of potential inhibitor against Leishmania donovani mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a vector-borne parasitic disease caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.